The menin fault lines emerge
With revumenib’s broader coverage Syndax tries to gain ground on Kura’s ziftomenib, but hits a new snag.
With revumenib’s broader coverage Syndax tries to gain ground on Kura’s ziftomenib, but hits a new snag.
